Deciphera issued a press release today sharing the results of an exploratory analysis of data using circulating tumor DNA (ctDNA) from the INTRIGUE Phase 3 clinical study of ripretinib and announcing plans to initiate INSIGHT.
In this webinar, “The Emerging Role of Circulating Tumor DNA in Gastrointestinal Stromal Tumor”, Dr. Bialick discussed recent data looking at treatment outcomes based off KIT resistant mutations identified by circulating tumor DNA in patients with GIST.
Dr. Ciara Kelly of Memorial Sloan Kettering Cancer Center at presented The Role of ctDNA in GIST at New Horizons 2019 in Wayne, NJ.
